DIagnostics, Fatty Acids and Vitamin D in SCA

• Register: ClinicalTrials.gov
• Last refreshed on: 24 August 2021
• Main ID: NCT02886273
• Date of registration: 23/08/2016
• Prospective Registration: No
• Primary sponsor: Helse Stavanger HF
• Public title: DIagnostics, Fatty Acids and Vitamin D in SCA DIFAD-SCA
• Scientific title: DIagnostics, RBC Levels of n-3 Fatty Acids and Serum Vitamin D in Patients With Out-of-Hospital Cardiac Arrest (OHCA)
• Date of first enrolment: January 2007
• Target sample size: 116
• Recruitment status: Active, not recruiting
• URL: https://clinicaltrials.gov/show/NCT02886273
• Study type: Observational [Patient Registry]

Countries of recruitment

Norway

Contacts

• Name: Dennis WT Nilsen, MDd PhD
• Affiliation: Helse Stavanger HF

Key inclusion & exclusion criteria

Inclusion Criteria:

1. Age > 18 years

2. OHCA of assumed cardiac etiology

3. Documented first recorded heart rythm

Exclusion Criteria:

1. Evidence of non-cardiac death (including cerebral etiology and pulmonary embolism)

2. OHCA due to cardiac tamponade.



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Ventricular Fibrillation

Out-of-Hospital Cardiac Arrest

Intervention(s)

Other: Group 3

Other: Group 1

Other: Group 2

Other: Group 4

Primary Outcome(s)

Early diagnostic performance of copeptin in Out-of-Hospital Cardiac arrest (OHCA) due to ventricular fibrillation (VF) [Time Frame: 48 hours]

Secondary Outcome(s)

EPA and DHA as compared to other fatty acids in red blood cell membranes from patients with OHCA [Time Frame: 48 hours]

Survival rate in OHCA with documented ventricular fibrillation [Time Frame: 1 month]

25-hydroxy (OH)-vitamin D in subjects with OHCA due to ventricular fibrillation (VF) [Time Frame: 48 hours]

Secondary ID(s)

StavangerSCA

Source(s) of Monetary Support

Please refer to primary and secondary sponsors